Drugmaker Pfizer decides not to break up business

SHARE Drugmaker Pfizer decides not to break up business
pfizer_split_decision_rumi.jpg

Pfizer will not split into two publicly traded companies. | AP file photo

TRENTON, N.J. — Drug giant Pfizer says it won’t split into two publicly traded companies, despite pressure from investors frustrated by its lagging stock price, ending years of Wall Street speculation over its strategy and future.

The biggest U.S.-based drugmaker said Monday it believes it is best positioned to maximize shareholder value in its current form, but it reserves the right to split in the future if the situation changes. Pfizer acquired Lake Forest’s Hospira for about $17 billion in September 2015.

For several years, the maker of Viagra and the pain treatment Lyrica has been under growing pressure from analysts and investors who argued that by splitting up, the resulting two companies might grow faster than one.

As a result, Pfizer has been reporting detailed financial results for each of its business segments, information that would be required by regulators for a split. Earlier this year, Pfizer promised a decision by the end of the year, but then it reorganized and renamed those segments — a sign a breakup was less likely.

Chances of the breakup began to fade even more over the summer, due in part to increasing sales for key new drugs from Pfizer and rising prospects for its drugs under development.

Pfizer CEO Ian Read told analysts last month that the prospect of a split was not a “make-or-break decision” for the company. The company recently said it had spent $600 million on preparations for such a split.

“Given that Pfizer has been talking down expectations for a separation in recent months, we think the stock will only be down modestly on this news,” Jeffries analyst Jeffrey Holford wrote to investors.

Shares of Pfizer Inc. fell 70 cents, or 2 percent, to $33.56 in afternoon trading Monday. The stock is up about 5.4 percent over the past year.

Pfizer said Monday that a split would not help the competitive positioning of its businesses, and such a move would create disruptions and increased costs.

The drugmaker’s most likely path forward involves hunting for more acquisition targets, according to Bernstein analyst Dr. Tim Anderson, who had pressed Pfizer repeatedly on its quarterly results conference calls to break up.

Pfizer has been buying several companies and products to help make up for a wave of sales losses to cheaper, generic competition, most notably for the cholesterol pill Lipitor. It also attempted and failed at two mega-acquisitions, of Britain’s AstraZeneca Plc in 2014 and this year of Ireland’s Allergan Plc.

Both those deals had been structured as tax inversions, meant to allow Pfizer to move its headquarters from New York — but just on paper — to a country with lower tax rates to reduce its U.S. tax bill. AstraZeneca rebuffed Pfizer, and the U.S. Treasury Department set up new rules that effectively blocked the Allergan acquisition.

Last month, Pfizer said it would spend about $14 billion to buy cancer drug developer Medivation, and it is buying rights to AstraZeneca’s portfolio of approved and experimental antibiotic and antifungal pills. In June, Pfizer completed a $5.2-billion acquisition of Anacor Pharmaceuticals Inc., which could get a new eczema drug, crisaborole, approved by January.

“A critic could argue that Pfizer is back to being the same old Pfizer as before, relying on (mergers and acquisitions) to grow and to refill its pipeline, but at the expense of growing larger in the process depending on the size of deals it chases,” Anderson said in a research note.

The Latest
The man was shot in the left eye area in the 5700 block of South Christiana Avenue on the city’s Southwest Side.
Most women who seek abortions are women of color, especially Black women. Restricting access to mifepristone, as a case now before the Supreme Court seeks to do, would worsen racial health disparities.
The Bears have spent months studying the draft. They’ll spend the next one plotting what could happen.
Woman is getting anxious about how often she has to host her husband’s hunting buddy and his wife, who don’t contribute at all to mealtimes.
He launched a campaign against a proposed neo-Nazis march at a time the suburb was home to many Holocaust survivors. His rabbi at Skokie Central Congregation urged Jews to ignore the Nazis. “I jumped up and said, ‘No, Rabbi. We will not stay home and close the windows.’ ”